A simple, non-invasive gene therapy restores sight
Kurzweil Network - 14-Jun-2013Researchers have developed an new method for inserting genes into retina cells. It is easier and...
Join the club for FREE to access the whole archive and other member benefits.
Co-Founder at 4D Molecular Therapeutics and Ignite Immunotherapies.
David Schaffer, Ph.D. is our co-founder and has served as our Chief Scientific Advisor and a member of our board of directors since our inception in 2013. Dr. Schaffer has served as a Professor of Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, and the Helen Wills Neuroscience Institute at the U.C. Berkeley since 1999 and has served as the Director of the Berkeley Stem Cell Center since 2011.
He currently serves on the board of directors of the following publicly-held company: uniQure NV since January 2014. Dr. Schaffer received a B.S. in Chemical Engineering from Stanford University in 1993. He earned his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology in 1998.
Visit website: https://www.4dmoleculartherapeutics.com/people/david-schaffer-phd/
See also: 4DMT - Gene therapy company.
Details last updated 26-Nov-2020
Researchers have developed an new method for inserting genes into retina cells. It is easier and...